Cellular Mechanisms Mediating Exercise-Induced Protection against Cardiotoxic Anthracycline Cancer Therapy
Cells · 2023
DOI: 10.3390/cells12091312 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, 2023. Verfasst von Sanela Dozic und 5 weiteren Autor:innen. Beteiligte Einrichtung: Central Clinical School, Monash University, Melbourne, VIC 3004, Australia. Hauptthemen laut MEDLINE: Antineoplastic Agents, Heart Failure, Neoplasms. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 127 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Monash University, National Heart Foundation of Australia, Health Research Council of New Zealand.
Abstract (Originalsprache)
Anthracyclines such as doxorubicin are widely used chemotherapy drugs. A common side effect of anthracycline therapy is cardiotoxicity, which can compromise heart function and lead to dilated cardiomyopathy and heart failure. Dexrazoxane and heart failure medications (i.e., beta blockers and drugs targeting the renin–angiotensin system) are prescribed for the primary prevention of cancer therapy-related cardiotoxicity and for the management of cardiac dysfunction and symptoms if they arise during chemotherapy. However, there is a clear need for new therapies to combat the cardiotoxic effects of cancer drugs. Exercise is a cardioprotective stimulus that has recently been shown to improve heart function and prevent functional disability in breast cancer patients undergoing anthracycline chemotherapy. Evidence from preclinical studies supports the use of exercise training to prevent or attenuate the damaging effects of anthracyclines on the cardiovascular system. In this review, we summarise findings from experimental models which provide insight into cellular mechanisms by which exercise may protect the heart from anthracycline-mediated damage, and identify knowledge gaps that require further investigation. Improved understanding of the mechanisms by which exercise protects the heart from anthracyclines may lead to the development of novel therapies to treat cancer therapy-related cardiotoxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Central Clinical School, Monash University, Melbourne, VIC 3004, Australia.
- Baker Heart and Diabetes Institute, Melbourne, VIC 3004, Australia.
- Department of Cardiometabolic Health, The University of Melbourne, Parkville, VIC 3010, Australia.
- Department of Anatomy & Physiology, The University of Melbourne, Parkville, VIC 3010, Australia.
- Department of Microbiology, Anatomy, Physiology & Pharmacology, La Trobe University, Bundoora, VIC 3086, Australia.
- Department of Physiology, University of Auckland, Auckland 1023, New Zealand.
Förderung
- Monash University
- National Heart Foundation of Australia
- Health Research Council of New Zealand
- Marsden Fund of New Zealand
- National Health and Medical Research Council of Australia
Zitieren
APA
Dozic, S., Howden, E. J., Bell, J. R., Mellor, K. M., Delbridge, L. M. D., & Weeks, K. L. (2023). Cellular Mechanisms Mediating Exercise-Induced Protection against Cardiotoxic Anthracycline Cancer Therapy. Cells. https://doi.org/10.3390/cells12091312
Vancouver
Dozic S, Howden EJ, Bell JR, Mellor KM, Delbridge LMD, Weeks KL. Cellular Mechanisms Mediating Exercise-Induced Protection against Cardiotoxic Anthracycline Cancer Therapy. Cells. 2023. doi:10.3390/cells12091312
BibTeX
@article{Dozic2023,
author = {Dozic, Sanela and Howden, Erin J and Bell, James R and Mellor, Kimberley M and Delbridge, Lea M D and Weeks, Kate L},
title = {Cellular Mechanisms Mediating Exercise-Induced Protection against Cardiotoxic Anthracycline Cancer Therapy},
journal = {Cells},
year = {2023},
doi = {10.3390/cells12091312}
}
EUVIMED